Association between COVID-19 Primary Vaccination and Severe COVID-19 [Robalo et al. 2022]

‘Vaccines’ published a study by Robalo and colleagues on the effectiveness of COVID-19 vaccines on developing several severe health outcomes of COVID-19 among COVID-19 hospitalised patients. Data were derived from the national COVID-19 surveillance registries. The study includes 2493 COVID-19 patients hospitalised across 73 Belgian hospitals in Belgium during August 2021– November 2021 (when the Delta variant was predominant). Analyses adjusted for patient, hospital and vaccination characteristics. Results indicate that hospitalised COVID-19 patients with a primary vaccination schedule had lower odds of progressing to severe disease and in-hospital death than unvaccinated patients. Among the vaccinated patients older than 75 years, mRNA vaccines (e.g., Pfizer and Moderna) and AstraZeneca seemed to confer similar protection, while one dose of Johnson & Johnson showed lower protection in this age category. Overall, a primary vaccination schedule protects against worsening of COVID-19 to severe outcomes among hospitalised patients.

The full article is available via:






HELICON is funded by the Belgian Federal Science Policy (BELSPO) through the BRAIN-be 2.0 (2018-2023) programme.

BRAIN-be logoBELSPO logo

Information sheet for participants: EN • NL • FR

Project coordinator

Prof. dr. Brecht Devleesschauwer

Sciensano, Department of Epidemiology and Public Health, Service Health Information